Westlake Vitae Completes Tens of Millions RMB Strategic Financing to Advance Integrated Precision Diagnostics Solutions

Recently, Westlake Vitae (Hangzhou) Diagnostics Co., Ltd. (“Westlake Vitae”), a leading enterprise in the field of red blood cell folate mass spectrometry, announced the completion of a strategic financing round worth tens of millions of yuan. The investment was made by Hongjia Fund, with Qifeng Capital serving as the exclusive financial advisor. The funds will be used for R&D investment, market expansion, and other purposes.

Xihu Weitai is dedicated to delivering one-stop precision medicine solutions through cutting-edge diagnostic technologies. Its business portfolio spans third-party medical testing, clinical mass spectrometry applications, and mass spectrometry reagent kits. The company has established third-party precision medicine laboratories in Beijing and Hangzhou, built a GMP-compliant production center, and set up an R&D subsidiary in Australia, among other operational segments.

Professor Shi Hongjun, the company’s founder, serves as Director of the Laboratory for Cardiac Development and Regeneration at the School of Medicine, Westlake University. He is dedicated to researching the pathogenic mechanisms of congenital heart disease. His team was the first to discover that embryonic vitamin B3 (niacin) deficiency can lead to multi-organ malformations, while prenatal niacin supplementation can completely prevent these defects. These findings were published in The New England Journal of Medicine in 2017.

Westlake Vitae leverages innovative testing categories as an entry point to provide mass spectrometry- and sequencing-based diagnostic and intervention solutions tailored for maternal and child health, reproductive medicine, and chronic disease populations. By establishing comprehensive medical solution pathways, the company delivers holistic solutions to clinical disciplines. Currently, Westlake Vitae has partnered with nearly 1,000 hospitals, universities, and national-level research institutions across China, collaborating on multiple projects that span all provinces. It has built a database of hundreds of thousands of individuals focused on red blood cell folate metabolism and has developed an integrated targeted metabolomics clinical diagnostic and intervention solution characterized by B-vitamin testing in red blood cells and aimed at monitoring active folate metabolic cycles. This has positioned Westlake Vitae as a leading enterprise in the field of red blood cell folate diagnostics for maternal and child reproductive health. With a robust pipeline of technical products, expanding scientific collaborations, numerous published academic findings, and rapid revenue growth, Westlake Vitae has successfully completed this round of strategic financing amounting to tens of millions of RMB. Looking ahead, Westlake Vitae will continue to deepen its collaboration with clinical practices, providing holistic solutions grounded in evidence-based medicine through the translation of scientific research.

Beijing Hongjia Private Equity Fund Management Co., Ltd. specializes in equity investments within the healthcare and medical sector. Its team comprises professionals with multidisciplinary backgrounds, each possessing over ten years of experience in either equity investment or the healthcare industry. The company collaborates closely with industrial groups to extensively identify investment opportunities in traditional Chinese medicine (TCM) and ethnic medicine, as well as consumer health targets supported by robust clinical evidence, thereby delivering dual empowerment through industrial integration and capital investment.

Springhill Capital is the boutique investment banking arm under Springhill, consistently dedicated to connecting top-tier projects with leading funds. It has supported and nurtured a cohort of sector-leading enterprises in niche markets such as biotechnology, medical technology, and high-end upstream industrial sectors.

Qifeng provides full-cycle capital services to enterprises, with business segments including: 1) Qifeng Capital: boutique investment banking services; 2) Qishi Dingfeng: early-stage incubation/investment; 3) Qifeng Integration: M&A integration and fund exits.